Liver Diseases Clinical Trial
Official title:
Patient Understanding of LiverMultiScan
Verified date | January 2018 |
Source | Perspectum Diagnostics Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a qualitative study to determine which factors affect the patient experience of having a liver MRI, what information patients would like to receive after their MRI, and how patients would like this information communicated to them.
Status | Completed |
Enrollment | 101 |
Est. completion date | December 2017 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - Individuals with experience of liver disease. - Individuals over the age of 16. - Individuals willing to give informed consent for participation in the study. Exclusion Criteria: - Individuals with any contraindication to magnetic resonance imaging. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR) | Oxford | Oxfordshire |
Lead Sponsor | Collaborator |
---|---|
Perspectum Diagnostics Ltd |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Factors effecting MRI experience and understanding. | This will be analysed based on themes and trends emanating from answers within the focused interview and questionnaire following the scan, and results feedback. | Immediately (within 1 hour) after undergoing the MRI scan, and receiving results feedback. | |
Secondary | Comparison of MRI to ultrasound scan in terms of patient experience. | This will be analysed based on themes and trends emanating from answers within the focused interview and questionnaire following the scan, and results feedback. | Immediately (within 1 hour) after undergoing an MRI scan, and ultrasound (FibroScan) scan. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05255042 -
Tissue Models for Liver Disease
|
||
Completed |
NCT04473482 -
Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Recruiting |
NCT03773887 -
Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease
|
N/A | |
Recruiting |
NCT00345930 -
DILIN - Prospective Study
|
||
Completed |
NCT00148031 -
Improving Hepatitis C Treatment in Injection Drug Users
|
Phase 4 | |
Terminated |
NCT00031135 -
Total Parenteral Nutrition-Associated Liver Disease
|
Phase 2 | |
Completed |
NCT00005305 -
Hepatitis Delta Infections in Hemophiliacs
|
N/A | |
Completed |
NCT00005304 -
Delta Hepatitis and Liver Disease in Hemophiliacs
|
||
Completed |
NCT00222664 -
Qidong Hepatitis B Intervention Study
|
Phase 4 | |
Recruiting |
NCT06195917 -
Robotic-assisted Percutaneous Transhepatic Puncture
|
N/A | |
Recruiting |
NCT04551742 -
Social & Contextual Impact on Children Undergoing Liver Transplantation
|
||
Completed |
NCT04782050 -
Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation
|
N/A | |
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Recruiting |
NCT04518852 -
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
|
Phase 2 | |
Recruiting |
NCT05499585 -
Treating Pediatric NAFLD With Nutrition
|
N/A | |
Terminated |
NCT03396705 -
Liver Regeneration
|
||
Completed |
NCT04341012 -
Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases
|
||
Recruiting |
NCT05733832 -
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
|
N/A |